GRAIL, LLC (GRAL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GRAIL, LLC (GRAL) has a cash flow conversion efficiency ratio of -0.035x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-86.99 Million) by net assets ($2.50 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of GRAIL, LLC to measure how much of total assets are equity-financed.
GRAIL, LLC - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how GRAIL, LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore GRAL long-term investments to assets to see how much of total assets are deployed in long-term investments.
GRAIL, LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRAIL, LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZIP Co Ltd
AU:ZIP
|
-0.205x |
|
Zhejiang Provincial New Energy Investment Group Co Ltd
SHG:600032
|
0.139x |
|
American Eagle Outfitters Inc
NYSE:AEO
|
0.032x |
|
Ningbo Zhenyu Technology Co. Ltd.
SHE:300953
|
0.016x |
|
Fabege AB
ST:FABG
|
0.023x |
|
Sinomag Technology Co Ltd
SHE:300835
|
0.011x |
|
KWS SAAT SE & Co. KGaA
F:KWS
|
-0.054x |
|
Nektar Therapeutics
NASDAQ:NKTR
|
-0.077x |
Annual Cash Flow Conversion Efficiency for GRAIL, LLC (2018–2025)
The table below shows the annual cash flow conversion efficiency of GRAIL, LLC from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see GRAL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.58 Billion | $-299.01 Million | -0.116x | +49.69% |
| 2024-12-31 | $2.50 Billion | $-577.16 Million | -0.231x | -41.09% |
| 2023-12-31 | $3.65 Billion | $-595.80 Million | -0.163x | -35.25% |
| 2022-12-31 | $4.65 Billion | $-561.31 Million | -0.121x | -65.57% |
| 2021-12-31 | $9.43 Billion | $-688.13 Million | -0.073x | +82.33% |
| 2020-12-31 | $561.84 Million | $-232.00 Million | -0.413x | +7.51% |
| 2019-12-31 | $550.53 Million | $-245.79 Million | -0.446x | -28.09% |
| 2018-12-31 | $600.37 Million | $-209.26 Million | -0.349x | -- |
About GRAIL, LLC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides deve… Read more